The JPIAMR Steering Committee (SC) provides steering direction of the JPIAMR and strategic input to undertake the JPIAMR mission. The SC meets regularly to discuss strategic issues, develop proposals for the MB and follows the implementation of activities by the JPIAMR Secretariat.
Steering Committee Members
Jan-Ingvar Jönsson, Sweden, Chair
Jan-Ingvar Jönsson is Vice-Chancellor and Professor at Linköping University in Sweden. He was member of the Scientific Council for Medicine and Health at the Swedish Research Council during the period , and from until the summer of he was secretary general of the Swedish Research Council, with scientific responsibility for medicine and health. Prof. Jönsson holds several national commissions, and in he was appointed to lead the newly established National research programme in antibiotic resistance in Sweden. He is national representative of several international organisations and is since chair of JPIAMR. He is also involved in collaboration between several other research funding agencies and policy makers worldwide.
Marie-Cécile Ploy, France, Vice Chair
Marie-Cécile Ploy, PharmD, PhD, is a Professor of Microbiology at the
Retiring Vice-Chancellor Helen Dannetun remembered her own installation in her speech, and quoted then University Chancellor Lars Haikola: “The post of vice-chancellor means – are you ready? – being head of the agency, company director, colleague, development manager, fundraiser, ambassador, negotiator, sounding board, symbol, team leader, student partner, intelligence analyst, strategist and tactician”. “And in addition”, continued Helen Dannetun, “we have a global pandemic, with the need to work remotely, use distance education, and master new digital tools.”
Collaboration
Helen Dannetun places the vice-chancellor’s chain of office around Jan-Ingvar Jönsson’s neck. Photo credit Magnus Johansson“Leading a university with 32, student“I wonder if it’s possible to reschedule the interview to next Friday instead”, asks Jan-Ingvar Jönsson politely by email.
A meeting about EU collaboration in COVID research has been scheduled, and as secretary general of the Swedish Research Council with responsibility for health and medicine, Jan-Ingvar is to participate as representative for the Swedish government.
It’s the end of April , we’re living in remarkable times, and Linköping University remains in distance mode. Initially, Jan-Ingvar Jönsson had a reasonable amount to look after (according to his standards). But in the middle of April, the government allocated SEK million for virus research, and suddenly he had more than enough on his plate.
Jan-Ingvar Jönsson must log in to a never-ending stream of meetings, such as the collaboration group under the European Commission, international researcher groups within WHO, colleagues in Nordic collaboration groups, or Swedish actors involved in clinical studies of COVID
“We have to coordinate so that countries do not unnecessarily repeat work. And we need a structured collaboration so that we can share new results”, he says.
The scientific community is under enormous pr
Jan-Ingvar Jönsson
Jan-Ingvar Jönsson, född 28 februari , är en svensk professor i medicinsk cellbiologi[2] och från 1 juli rektor vid Linköpings universitet.[3]
Jönsson genomförde sin medicinska grundutbildning vid Lunds universitet under åren –[4][1] där även en period av forskning genomfördes vid Max Planck-institutet för immunbiologi i Freiburg, Tyskland.
– arbetade Jönsson som postdoktor vid Hospital for Sick Children Research Institute, Toronto, Kanada på avdelningen för Immunologi och cancer[4]. Därefter följde en tjänst som forskarassistent, en så kallad cancerforskartjänst, vid Uppsala universitet som finansierats av Cancerfonden[1][4].
Efter ett antal år vid Lunds universitet började Jönsson arbeta vid Linköpings universitet år inom medicinsk cellbiologi. År fick Jönsson sin professur i medicinsk cellbiologi[4]. Han leder en forskargrupp som arbetar med en teknologi kallad masscytometri för att undersöka blodstamceller[1] med syftet att ta reda på varför patienter med leukemi reagerar olika på cellgiftsbehandling[5].
Från 1 januari blev Jönsson huvudsekreterare för ämnesområdet medicin och hälsa vid Vetenskapsrådet[6].
Källor
[red.